보고서 요약(국문)

시장 개요
전 세계 희귀 혈액 질환 시장 규모는 2022년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 XX%입니다.
소수의 사람들에게 희귀 혈액 질환이 나타납니다. 이러한 질환은 혈소판, 적혈구 또는 백혈구에 영향을 미쳐 산소 전달 및 감염 방어 능력을 저해합니다. 혈구탐식성 림프조직구증과 같은 일부 질환은 치명적일 수 있습니다. 혈액 질환은 암성 및 비암성 모두 존재하며, 가장 흔한 비암성 혈액 질환은 빈혈입니다.
시장 동향
전 세계 희귀 혈액 질환 시장 성장을 이끄는 주요 요인은 특정 혈액 질환의 발병률 증가입니다. 주요 기업들은 질환 발전을 촉진하고 새로운 치료법 개발을 위해 더 많은 임상 시험을 진행하고 있습니다.
특정 혈액 질환의 발병률 증가는 희귀 혈액 질환 시장 성장을 견인하는 핵심 요소입니다.

혈액학자들은 빈혈, 다발성 골수종, 백혈병, 겸상 적혈구 빈혈과 같은 수많은 혈액 질환의 발생률 증가로 인해 다양한 진단 절차에 집중하고 있습니다. 혈액학자들은 신속한 진단이 요구되는 시대에 정확한 진단 과정을 통해 치료 과정을 개선하고자 노력하고 있습니다. 다양한 혈액 질환을 식별해야 할 필요성이 증가함에 따라 혈액학자들의 진단 능력 향상에 대한 관심은 더욱 높아졌습니다.
미국 국립보건원(National Library of Health, U.S., 2022)에 따르면 85세 이상 노인의 20% 이상이 빈혈의 영향을 받고 있습니다. 요양원 거주자의 경우 빈혈 발생률은 50~60%에 달합니다. 철분, 엽산 또는 비타민 B12 부족과 같은 영양 결핍이 노인 빈혈의 주요 원인으로, 환자의 약 3분의 1을 차지합니다. 나머지 3분의 1은 만성 염증이나 신부전이 원인입니다. Statista 연구에 따르면 2021년 전 세계적으로 약 23만 4천 건의 혈우병 사례가 확인될 것으로 추정됩니다. 또한 같은 시기에 폰 빌레브란트병 환자는 9만 명 더 발생했습니다. 이 두 가지 유전성 질환은 혈액 응고 장애로 인해 출혈을 유발합니다. 이러한 요인들로 인해 희귀 혈액 질환 시장은 예측 기간 동안 지속적으로 성장세를 보일 것으로 예상됩니다.
하지만 희귀 혈액 질환 진단 비용이 높은 점은 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.
희귀 혈액 질환 시장은 질병 진단 비용이 높고, 불리한 의료비 상환 정책 또한 시장 성장을 저해하는 주요 요인으로 작용할 것입니다.

COVID-19 영향 분석
대부분의 산업은 최근 몇 달 동안 부정적인 영향을 받았습니다. 이는 전 세계 규제 기관의 다양한 예방적 봉쇄 조치 및 기타 제한으로 인해 공급망과 제조 공정에 큰 차질이 발생했기 때문입니다. 희귀 혈액 질환 시장도 예외는 아닙니다.

또한, 팬데믹으로 인해 대부분의 사람들의 전반적인 경제 상황이 악화되면서 불필요한 지출을 줄이려는 경향이 커짐에 따라 소비자 수요가 감소했습니다. 이러한 요인들은 예측 기간 동안 시장에 부정적인 영향을 미칠 것으로 예상됩니다. 그러나 관련 정부 기관에서 봉쇄 조치를 해제하기 시작하면 전 세계 희귀 혈액 질환 시장은 반등할 것으로 전망됩니다.
세그먼트 분석
성인 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
혈우병은 유전성 출혈 질환으로 혈액 응고가 비정상적으로 이루어지는 질환입니다. 자발적 출혈뿐만 아니라 사고나 수술 후 출혈도 발생할 수 있습니다. 혈우병 A는 주로 남성에게 발생하지만 여성에게도 발생할 수 있습니다. 신생아 5,000명 중 약 1명꼴로 혈우병 A가 발병합니다. 혈우병 A 환자의 약 60%는 중증 혈우병을 앓습니다.

미국 암 협회의 예측에 따르면, 2022년 해당 주에서 급성 골수성 백혈병(AML) 신규 환자가 약 20,050명 발생할 것으로 예상되며, 대부분 성인 환자에게서 나타날 것입니다. AML로 인한 사망자는 11,540명이며, 이 또한 거의 모두 성인에게서 발생할 것입니다.
2019년 4월 인디언 익스프레스 뉴스 기사에 따르면, 혈우병 치료를 위한 의료 기술의 발전에도 불구하고, 외딴 지역에는 적절한 진단 시설이 부족하여 위험한 혈액 질환을 앓고 있는 인도인의 약 80%가 진단받지 못하고 있는 것으로 추정됩니다. 4월 17일 세계 혈우병의 날을 앞두고, 의사들은 인도의 혈우병 환자 수가 약 20만 명으로 세계에서 두 번째로 많다고 예측했습니다. 이 만성 출혈 질환은 혈액 응고를 방해합니다. 이는 큰 시장 기회를 창출하며 향후 몇 년 동안 성장을 촉진할 것입니다.
지리적 분석
북미는 전 세계 희귀 혈액 질환 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.

북미는 인구 규모, 우수한 의료 인프라, 높은 소득 수준을 바탕으로 전 세계 희귀 혈액 질환 시장을 주도하고 있습니다. 이 시장은 예측 기간 동안 비교적 완만한 성장세를 보일 것으로 예상됩니다. 고령 인구 증가와 희귀 혈액 질환 유병률 상승으로 인해 북미 희귀 혈액 질환 시장은 성장할 전망입니다. 또한, 주요 제약 회사들의 신약 개발 연구 활동에 힘입어 향후 몇 년 동안 이 산업은 급속한 성장을 경험할 것입니다.
미국 질병예방건강증진국(Office of Disease Prevention and Health Promotion)의 2019년 보고서에 따르면, 수백만 명을 포함한 수많은 미국인이 겸상 적혈구병 및 혈우병과 같은 혈액 질환을 유발할 수 있는 유전자의 보인자입니다. Healthy People 2030의 목표는 혈액 질환을 가진 사람들의 건강과 삶의 질을 향상시키는 것입니다.
미국에서는 혈액 질환의 일종인 겸상 적혈구병 환자가 10만 명이 넘습니다. 수혈은 질병 예방 및 치료에 도움이 될 수 있으며, 하이드록시우레아 사용 확대와 같은 중재적 치료는 겸상 적혈구 질환 환자의 건강 결과를 개선할 수 있습니다. 의료 인프라 개선, 의료비 지출 증가, 그리고 정부의 적극적인 지원은 지역적 시장 확장을 더욱 촉진할 것입니다. 예를 들어, 미국 국립심장폐혈연구소(NHLBI)의 지원을 받은 과학자들은 2021년 6월 혈우병 환자를 위한 생명을 구하는 치료법을 발견했으며, 현재 혈우병 치료를 위한 유전자 치료법을 연구하고 있습니다.
경쟁 환경
희귀 혈액 질환 시장은 노바티스, 브리스톨-마이어스 스큅, 노보 노르디스크, F. 호프만-라로슈, 엠마우스 메디컬, 화이자, 바이엘, 암젠, CSL 베링 등 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 기업들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 통해 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 12월 제64회 미국 혈액학회(ASH) 연례 회의에서는 임상 단계 생명공학 회사인 베가 테라퓨틱스(Vega Therapeutics, Inc.)가 개발한 최초의 항체 치료제인 VGA039가 소개되고 공개 발표되었습니다.
노바티스(Novartis AG)

개요: 노바티스(Novartis AG)는 전문의약품, 일반의약품, 안과 제품의 개발, 생산 및 판매를 전문으로 하는 헬스케어 회사입니다. 감염, 암, 심혈관 질환, 피부 질환, 신경 장애, 안과 및 호흡기 질환 치료제를 제공합니다. 산도즈(Sandoz)를 통해 바이오시밀러와 제네릭 의약품을 제공합니다. 노바티스는 노바티스 생의학 연구소(Novartis Institutes for BioMedical Research, NIBR)를 통해 여러 질병 분야에서 연구를 수행합니다.

제품 포트폴리오:
노바티스 의약품 프로막타(Promacta): 프로막타는 중증 재생불량성 빈혈을 앓는 2세 이상 성인 및 소아 환자의 1차 치료를 위해 표준 면역억제 요법(IST)과 병용하여 사용하도록 적응증이 있습니다. 프로막타는 면역억제 요법에 충분한 반응을 보이지 않은 중증 재생불량성 빈혈 환자의 치료에 사용됩니다.
글로벌 희귀 혈액 질환 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 200페이지(약) 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global rare haematology market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).
A small number of individuals have rare blood diseases. They can impact platelets, red blood cells, or white blood cells, which makes it challenging to transfer oxygen and fight infections. A few conditions, such hemophagocytic lymphohistiocytosis, can be fatal. Cancerous and non-cancerous blood diseases both exist. The most prevalent non-cancerous blood condition is anemia.
Market Dynamics
The major factors driving the global rare haematology market are the rising incidence of certain blood diseases. More clinical trials are being conducted to promote progress and developing of novel treatments by the key players.
The rising incidence of certain blood diseases is the prime factor driving the growth of the rare haematology market.
Hematologists are concentrating on various detection procedures due to the rising occurrence of numerous blood disorders such as anemia, myeloma, leukemia, and sickle cell anemia. Hematologists are looking for improved treatment processes through accurate diagnosis processes as the requirement for conducting relatively rapid diagnosis processes is becoming the order of the day. Hematologists' attention to improving their diagnostic abilities has been further prompted by the increased necessity to identify various blood disorders.
More than 20% of those over the age of 85 are affected, according to the National Library of Health, U.S., 2022. In the population of nursing homes, anemia occurs 50% to 60% of the time. A dietary deficit, such as a lack of iron, folate, or vitamin B12, is the main cause of anemia in the elderly, accounting for about one-third of patients. There is proof of chronic inflammation or renal failure in another third of the individuals. And Statista research estimates that around 234 thousand hemophilia cases will be confirmed globally in 2021. And 90,000 more persons had von Willebrand disease at that time. These two hereditary illnesses that cause bleeding prevent blood from clotting correctly. Due to these factors, the market's growth will continue to pick up steam during the forecast timeframe.
Due to the high price of diagnosing rare haematology is expected to hamper the market’s growth.
The rare haematology market will face limitations due to the high price of the disease, and unfavorable reimbursement policies are also a key factor hindering the growth of the market.
COVID-19 Impact Analysis
The majority of industries have had unfavorable effects in recent months. This can be ascribed to major interruptions in their supply chains and manufacturing processes due to global regulatory agencies' various precautionary lockdowns and other restrictions. The market is no different.
Additionally, consumer demand has decreased as people have become more motivated to cut non-essential spending from their budgets as the general economic situation of most people has been badly impacted by the pandamic. The above factors are anticipated throughout the forecast period to impact the market negatively. However, the global rare hematology market is anticipated to rebound after the relevant governing bodies start pharmaceuticals lift such imposed lockdowns.
Segment Analysis
The adults segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The blood clots incorrectly as a result of hemophilia, an inherited bleeding disorder. Both spontaneous bleeding and bleeding after an accident or surgery may come from this. Hemophilia A primarily affects men, while it can also affect women. Hemophilia A affects about 1 in 5,000 newborns. A severe type of hemophilia A affects about 60% of those who suffer from it.
According to projections made by the American Cancer Society, there will be roughly 20,050 new cases of acute myeloid leukemia (AML) in the state in 2022, most of which will affect adults. AML will cause 11,540 deaths, almost all of which will be in adults.
According to the Indian Express News article from April 2019, approximately 80% of Indians with dangerous blood illness are believed to go undiagnosed since there aren't adequate diagnostic facilities in remote locations, despite advancements in medical technology for hemophilia treatment. Ahead of World Hemophilia Day on April 17, physicians projected that India, with about 200,000 cases, has the second-highest population of individuals with hemophilia. This chronic bleeding illness prevents blood from clotting. This opens up a large market opportunity and will spur growth in the upcoming years.
Geographical Analysis
North America holds the largest market share in the global rare haematology market.
North America dominates the global Rare Haematology market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period. Due to the growing elderly population and rising prevalence of rare blood disorders, the North American market for rare hematological disorders would rise. Additionally, the industry will experience a rapid expansion in the coming years due to the major pharmaceutical companies' research initiatives to create new drugs.
Numerous Americans, including millions of people, are carriers of genes that can lead to blood diseases like sickle cell disease and hemophilia, according to the Office of Disease Prevention and Health Promotion's 2019 report. The goal of Healthy People 2030 is to improve the health and standard of living of people with blood diseases.
In the U.S., sickle cell disease, a blood condition, affects more than 100,000 people. Blood transfusions can help avoid and treat problems, and interventions, such as plans to use more hydroxyurea, can improve the health outcomes of patients with sickle cell disease. The regional expansion will be further aided by improved healthcare infrastructure, rising healthcare spending, and helpful government efforts. For instance, scientists funded by the National Heart, Lung, and Blood Institute (NHLBI) in June 2021 discovered life-saving therapies for hemophilia patients and are currently working on gene therapy options to treat the condition.
Competitive Landscape
The Rare Haematology market is moderately competitive with local and global companies’ presence Novartis, Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., Bayer AG, Amgen Inc, CSL Behring LLC and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in December 2022, The 64th American Society of Hematology (ASH) Annual Meeting saw the introduction and public presentation of VGA039, a first-in-class antibody treatment developed by Vega Therapeutics, Inc., a clinical stage biotechnology company.
Novartis AG.
Overview: A healthcare company named Novartis AG (Novartis) specializes in developing, producing, and marketing prescription and over-the-counter medicines and eye care products. It offers medicines for infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis conducts research in several illness areas (NIBR).
Product Portfolio:
Novartis drug Promacta: PROMACTA is indicated in combination with standard immunosuppressive therapy (IST) for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. PROMACTA is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Theglobal Rare Haematology market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising incidence of certain blood diseases
4.1.1.2. More clinical trials are being conducted to promote progress
4.1.2. Restraints:
4.1.2.1. Due to the high price of diagnosing is expected to hamper the market’s growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Product Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
7.1.2. Market Attractiveness Index, By Product Class
7.2. Recombinant factor
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Plasma-derived factors
7.4. Extended Half-Life
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Rare blood cancers
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Platelet based disorders
8.4. Plasma disorders
8.5. Myeloproliferative disorders
8.6. Genetic hematology disorders
9. By Patient Age-Group
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
9.1.2. Market Attractiveness Index, By Patient Age-Group
9.2. Pediatrics (0-17)
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Adults (18+)
10. By Region
10.1. Introduction
10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age-Group
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Novartis AG
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Bristol-Myers Squibb Company
12.3. Novo Nordisk A/S
12.4. F. Hoffmann-La Roche Ltd
12.5. Emmaus Medical, Inc.
12.6. Pfizer Inc.
12.7. Bayer AG
12.8. Amgen Inc
12.9. CSL Behring LLC.
12.10. Vega Therapeutics Inc
LIST NOT EXHAUSTIVE
13. Global Rare Haematology Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us

언급된 주요 기업들

Novartis  AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., Bayer AG, Amgen Inc, CSL Behring LLC., Vega Therapeutics Inc

표 목록 (Tables)

List of Tables

Table 1 Global Rare Haematology Market Value, By Product Class, 2023, 2027 & 2031 ($ Million)

Table 2 Global Rare Haematology Market Value, By Indication, 2023, 2027 & 2031 ($ Million)

Table 3 Global Rare Haematology Market Value, By Patient Age-Group, 2023, 2027 & 2031 ($ Million)

Table 4 Global Rare Haematology Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 5 Global Rare Haematology Market Value, By Product Class, 2023, 2027 & 2031 ($ Million)

Table 6 Global Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 7 Global Rare Haematology Market Value, By Indication, 2023, 2027 & 2031 ($ Million)

Table 8 Global Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 9 Global Rare Haematology Market Value, By Patient Age-Group, 2023, 2027 & 2031 ($ Million)

Table 10 Global Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 11 Global Rare Haematology Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 12 Global Rare Haematology Market Value, By Region, 2022-2031 ($ Million)

Table 13 North America Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 14 North America Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 15 North America Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 16 North America Rare Haematology Market Value, By Country, 2022-2031 ($ Million)

Table 17 South America Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 18 South America Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 19 South America Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 20 South America Rare Haematology Market Value, By Country, 2022-2031 ($ Million)

Table 21 Europe Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 22 Europe Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 23 Europe Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 24 Europe Rare Haematology Market Value, By Country, 2022-2031 ($ Million)

Table 25 Asia-Pacific Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 26 Asia-Pacific Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 27 Asia-Pacific Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 28 Asia-Pacific Rare Haematology Market Value, By Country, 2022-2031 ($ Million)

Table 29 Middle East & Africa Rare Haematology Market Value, By Product Class, 2022-2031 ($ Million)

Table 30 Middle East & Africa Rare Haematology Market Value, By Indication, 2022-2031 ($ Million)

Table 31 Middle East & Africa Rare Haematology Market Value, By Patient Age-Group, 2022-2031 ($ Million)

Table 32 Novartis: Overview

Table 33 Novartis: Product Portfolio

Table 34 Novartis: Key Developments

Table 35 Bristol-Myers Squibb Company: Overview

Table 36 Bristol-Myers Squibb Company: Product Portfolio

Table 37 Bristol-Myers Squibb Company: Key Developments

Table 38 Novo Nordisk A/S: Overview

Table 39 Novo Nordisk A/S: Product Portfolio

Table 40 Novo Nordisk A/S: Key Developments

Table 41 F. Hoffmann-La Roche Ltd: Overview

Table 42 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 43 F. Hoffmann-La Roche Ltd: Key Developments

Table 44 Emmaus Medical, Inc.: Overview

Table 45 Emmaus Medical, Inc.: Product Portfolio

Table 46 Emmaus Medical, Inc.: Key Developments

Table 47 Pfizer Inc.: Overview

Table 48 Pfizer Inc.: Product Portfolio

Table 49 Pfizer Inc.: Key Developments

Table 50 Bayer AG: Overview

Table 51 Bayer AG: Product Portfolio

Table 52 Bayer AG: Key Developments

Table 53 Amgen Inc: Overview

Table 54 Amgen Inc: Product Portfolio

Table 55 Amgen Inc: Key Developments

Table 56 CSL Behring LLC: Overview

Table 57 CSL Behring LLC: Product Portfolio

Table 58 CSL Behring LLC: Key Developments

Table 59 Vega Therapeutics, Inc: Overview

Table 60 Vega Therapeutics, Inc: Product Portfolio

Table 61 Vega Therapeutics, Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 2 Global Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 3 Global Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 4 Global Rare Haematology Market Share, By Region, 2022 & 2030 (%)

Figure 5 Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 6 Global Rare Haematology Market Y-o-Y Growth, By Product Class, 2022-2030 (%)

Figure 7 Recombinant factor: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 8 Plasma-derived factors: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 9 Extended Half-Life: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 10 Global Rare Haematology Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 11 Rare blood cancers: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 12 Platelet based disorders: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 13 Plasma disorders: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 14 Myeloproliferative disorders: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 15 Genetic hematology disorders: Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 16 Global Rare Haematology Market Y-o-Y Growth, By Patient Age-Group, 2022-2030 (%)

Figure 17 Pediatrics (0-17): Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 18 Adults (18+): Global Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 19 Global Rare Haematology Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 21 North America Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 22 North America Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 23 North America Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 24 North America Rare Haematology Market Share, By Country, 2022 & 2030 (%)

Figure 25 South America Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 26 South America Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 27 South America Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 28 South America Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 29 South America Rare Haematology Market Share, By Country, 2022 & 2030 (%)

Figure 30 Europe Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 31 Europe Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 32 Europe Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 33 Europe Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 34 Europe Rare Haematology Market Share, By Country, 2022 & 2030 (%)

Figure 35 Asia-Pacific Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 36 Asia-Pacific Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 37 Asia-Pacific Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 38 Asia-Pacific Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 39 Asia-Pacific Rare Haematology Market Share, By Country, 2022 & 2030 (%)

Figure 40 Middle East & Africa Rare Haematology Market Value, 2022-2031 ($ Million)

Figure 41 Middle East & Africa Rare Haematology Market Share, By Product Class, 2022 & 2030 (%)

Figure 42 Middle East & Africa Rare Haematology Market Share, By Indication, 2022 & 2030 (%)

Figure 43 Middle East & Africa Rare Haematology Market Share, By Patient Age-Group, 2022 & 2030 (%)

Figure 44 Novartis: Financials

Figure 45 Bristol-Myers Squibb Company: Financials

Figure 46 Novo Nordisk A/S: Financials

Figure 47 F. Hoffmann-La Roche Ltd: Financials

Figure 48 Emmaus Medical, Inc.: Financials

Figure 49 Pfizer Inc.: Financials

Figure 50 Bayer AG: Financials

Figure 51 Amgen Inc: Financials

Figure 52 CSL Behring LLC: Financials

Figure 53 Vega Therapeutics, Inc: Financials

세계 희귀 혈액 질환 시장 – 2023-2030

Global Rare Haematology Market - 2023-2030